Heart Health Advances of Mounjaro in Comparison Study with Trulicity
Eli Lilly's new diabetes drug, Mounjaro, has demonstrated noteworthy benefits for heart health in a recent trial compared to Trulicity, an earlier treatment also from the company.
The trial revealed that Mounjaro achieved its primary goal of being equally effective as Trulicity in managing Type 2 diabetes alongside established cardiovascular disease. Eli Lilly contends that this strengthens the argument for making Mounjaro the preferred treatment option for individuals with Type 2 diabetes.
As the patent for Trulicity edges towards expiration in 2027, Mounjaro's role in the diabetes medication marketplace could see a marked rise.
Throughout this nearly five-year-long study, Mounjaro displayed an 8% reduction in the risk for cardiovascular incidents such as death, strokes, or heart attacks, when juxtaposed with Trulicity.
Eli Lilly's stock saw a slight dip as the trial results did not satisfy some analysts' expectations of surpassing Trulicity. Nonetheless, additional benefits of Mounjaro were observed, including a 16% reduction in mortality from any cause and enhanced kidney protection.
Healthcare professionals had anticipated Mounjaro might confer heart health advantages. Despite this, the level of reduced mortality from any cause was significant and clinically important, according to Dr. David Broome from the University of Michigan.
He emphasized these insights will aid in making informed decisions about treatment options for patients, which should account for various factors like insurance, side effects, and patient tolerance.
Dr. Howard Weintraub of NYU Langone Heart commended Mounjaro, albeit noting its tendency for more side effects compared to Trulicity. However, he questioned whether these findings would lead to increased usage given Mounjaro’s higher pricing structure.
Eli Lilly is poised to present more detailed results in upcoming medical forums, believing the data backs Mounjaro as the superior choice for those with both Type 2 diabetes and cardiovascular risks.
According to Ken Custer, president of Lilly Cardiometabolic Health, the trial significantly bolsters the case for Mounjaro, challenging any reason against prescribing it.
In the evolving landscape of diabetes and weight loss medications, Eli Lilly is distancing itself from competition. The company plans to submit these findings to regulatory authorities globally, eyeing potential approval in 2026.
Even if approved for heart disease treatment, Mounjaro's usage may not see substantial growth, as many current diabetes patients already present cardiovascular issues.
Market analysts predict Mounjaro’s adoption will continue, given its solid profile, despite comparisons showing it matches or slightly surpasses Trulicity's heart health benefits.
The safety profiles for both Mounjaro and Trulicity were similar to previous data, with the most common side effects being gastrointestinal and of mild to moderate intensity.



Leave a Reply